Treeway Licensing Deal with Specialised Therapeutics

Aug 28, 2023

Singapore, August 28th, 2023 –Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Netherlands based biotechnology company Treeway BV to commercialise a new therapy to treat Amyotrophic Lateral Sclerosis (ALS)¹ – the most...

Treeway announces first patient enrolled in the Phase 2a ASURE clinical trial exploring the safety and effectiveness of oral edaravone to delay disease progression in Alzheimer’s patients

Mar 6, 2023

Tilburg, March 6, 2023 – Treeway, in collaboration with the Alzheimer Drug Discovery Foundation (ADDF), announces today the successful enrollment of the first patient in the Alzheimer’s Disease Study Using Oral Edaravone (ASURE), Phase 2a clinical trial. The trial...

Ferrer announces first patient enrollment of FNP122 in ADORE Phase III clinical trial for Amyotrophic Lateral Sclerosis treatment

Nov 9, 2021

Barcelona,  November 9th, 2021 – Ferrer, an international pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has today announced the next major milestone in its mission to develop transformative therapies...

Ferrer and Treeway enter into licence agreement for the development and commercialisation of TW001/FNP122 for Amyotrophic Lateral Sclerosis

Oct 20, 2021

Barcelona and Tilburg, 20 October 2021 – Today, Ferrer, an international pharmaceutical company focused on pulmonary vascular and interstitial lung diseases and neurological disorders, and Treeway, a clinical-stage biotechnology company, announced they have entered...

Treeway Announces Promising Data from Phase I Clinical Trial of Lead

May 29, 2018

–Study suggests that novel oral formulation of edaravone improves bioavailability while remaining well tolerated–  Rotterdam, The Netherlands, May 29th2018 – Treeway, a biotech company developing therapies against amyotrophic lateral sclerosis (ALS), today announced...